Ligand id: 8717

Name: evinacumab

No information available.
Summary of Clinical Use
Evinacumab has reached Phase II clinical trial for its potential to treat homozygous familial hypercholesterolemia (HoFH). Click here to view ClinicalTrials.gov's full list of evinacumab trials.
Mechanism Of Action and Pharmacodynamic Effects
ANGPTL3 inhibits lipoprotein lipase (LPL) activity leading to increased level of lipids [1], and subsequently regulates very low density lipoprotein (VLDL) triglyceride levels [2]. The N-terminal coiled-coil region of ANGPTL3 inhibits LPL when expressed without the C-terminal fibrinogen region and therefore appears to confer its inhibitory function. The H4H1276S antibody clone in patent US9018356 B2, presumed to be evinacumab, inhibits the ANGPTL3-induced decrease in LPL activity in vitro [3], but does not block ANGPTL4-induced decrease in LPL activity. H4H1276S shows cross-species activity, inhibiting mouse and monkey ANGPTL3 at comparable levels to the human protein [3].